Want to see XLO full AI Analyst Report?
Top Page
Xilio Therapeutics
(NASDAQ:XLO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$8.00
▼(-11.60% Downside)
Action:Reiterated
Date:10/28/26
The score is held down primarily by heavy ongoing cash burn and continued net losses, despite strong revenue growth and very high gross margins. Technical conditions also remain weak with the price below key moving averages and negative momentum. Low leverage supports the balance sheet, but valuation signals are limited due to negative earnings and no dividend yield data.
Positive Factors
Revenue and gross margin
Strong collaboration-related revenue and an exceptionally high gross margin indicate that existing programs can generate substantial reported revenue with limited direct cost. Continued top-line growth provides resources for pipeline advancement, although durable earnings conversion remains unproven.
Negative Factors
Persistent cash burn
Large recurring operating and free-cash-flow deficits mean Xilio cannot currently fund its spending from operations. Continued development therefore depends on outside financing or partnerships, creating an enduring need to manage capital carefully as programs progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross margin
Strong collaboration-related revenue and an exceptionally high gross margin indicate that existing programs can generate substantial reported revenue with limited direct cost. Continued top-line growth provides resources for pipeline advancement, although durable earnings conversion remains unproven.
Read all positive factors
Xilio Therapeutics (XLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$52.71M
Dividend YieldN/A
Average Volume (3M)11.99K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue Growth327.25%
EPS Growth85.65%
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.49
Shares Outstanding6,580,153
10 Day Avg. Volume16,791
30 Day Avg. Volume11,986
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.12
Price to Sales (P/S)1.71
P/FCF Ratio-13.59
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit0.88
Enterprise Value/Ebitda-2.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$40.34M
Xilio Therapeutics Business Overview & Revenue Model
Company Description
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal an...
How the Company Makes Money
As a clinical-stage biotechnology company, Xilio Therapeutics has historically not generated meaningful recurring revenue from product sales because it does not have approved commercial products. Its funding and revenue, when present, are typicall...
Xilio Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.09M | 43.77M | 6.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 63.75M | 42.23M | 6.34M | 0.00 | 0.00 | -1.50M |
| EBITDA | -20.49M | -33.49M | -58.00M | -74.50M | -86.38M | -73.70M |
| Net Income | -21.83M | -35.04M | -58.24M | -76.40M | -88.22M | -75.80M |
Balance Sheet | ||||||
| Total Assets | 154.25M | 154.69M | 71.08M | 60.93M | 139.16M | 221.60M |
| Cash, Cash Equivalents and Short-Term Investments | 136.04M | 137.53M | 55.29M | 44.70M | 120.39M | 198.05M |
| Total Debt | 6.30M | 6.95M | 8.14M | 12.50M | 19.94M | 20.74M |
| Total Liabilities | 81.99M | 119.41M | 53.48M | 24.10M | 33.52M | 36.17M |
| Stockholders Equity | 72.26M | 35.27M | 17.60M | 36.83M | 105.65M | 185.43M |
Cash Flow | ||||||
| Free Cash Flow | -61.27M | -5.51M | -18.41M | -69.11M | -77.59M | -81.85M |
| Operating Cash Flow | -60.60M | -4.99M | -18.38M | -68.62M | -75.72M | -80.75M |
| Investing Cash Flow | -670.00K | -518.00K | -36.00K | -486.00K | -1.87M | -1.10M |
| Financing Cash Flow | 75.78M | 87.78M | 29.20M | -6.55M | -69.00K | 260.67M |
Xilio Therapeutics Technical Analysis
Negative
9.05
Price Trends
8.89
Negative
8.89
Negative
8.51
Negative
Market Momentum
-0.32
Positive
39.72
Neutral
18.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XLO, the sentiment is Negative. The current price of 9.05 is above the 20-day moving average (MA) of 8.66, above the 50-day MA of 8.89, and above the 200-day MA of 8.51, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 39.72 is Neutral, neither overbought nor oversold. The STOCH value of 18.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XLO.
Xilio Therapeutics Risk Analysis
Xilio Therapeutics disclosed 86 risk factors in its most recent earnings report. Xilio Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xilio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $53.06M | -0.96 | -150.47% | ― | ― | ― | |
46 Neutral | $78.19M | -6.23 | -200.67% | ― | ― | -39.90% | |
44 Neutral | $52.71M | -5.38 | -50.77% | ― | 327.25% | 85.65% | |
44 Neutral | $322.23M | -2.71 | -63.05% | ― | -51.65% | 91.93% | |
41 Neutral | $9.56M | -0.40 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
XLO
Xilio Therapeutics
8.01
-3.47
-30.23%
XFOR
X4 Pharmaceuticals
3.25
-0.56
-14.70%
LTRN
Lantern Pharma
0.64
-3.34
-83.92%
CNTB
Connect Biopharma Holdings
0.84
-0.70
-45.32%
OKYO
OKYO Pharma Limited Sponsored ADR
1.49
-1.06
-41.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.